Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599924 · ClinicalTrials.gov registry record · Phase 1
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
A Phase 1 study of Neoplasms and Colorectal Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 3
- Study locations
NCT00599924: Completed Phase 1 study of Neoplasms and Colorectal Neoplasms, sponsored by Pfizer.
NCT00599924 is a Phase 1 study of Neoplasms and Colorectal Neoplasms that has completed, run by Pfizer. The registered enrollment target is 53 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00599924, a Phase 1 study of Neoplasms and Colorectal Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX \[Leucovorin + Fluorouracil (5-FU) + Oxaliplatin\]. Three different dosing regimens with starting doses of sunitinib at 37.5 mg/day (Schedule 2/2, Schedule 4/2, and Continuous Dosing) were tested in patients with advanced solid tumors, including colorectal cancer.
Primary Outcome
All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) were reported.
Conditions Studied
Interventions
- DRUG sunitinib + FOLFOX
Study Locations (3)
Colorado
- Pfizer Investigational Site - Aurora
Tennessee
- Pfizer Investigational Site - Nashville
Texas
- Pfizer Investigational Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
What the finished NCT00599924 record still lists
NCT00599924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which sunitinib + FOLFOX is the first listed.
NCT00599924 reports a single indexed study location in Colorado, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT00599924 about?
NCT00599924 is a clinical study titled "Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors". This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX \[Leucovorin + Fluorouracil (5-FU) + Oxaliplatin\]. Three different dosing regimens with starting doses of sunitinib at 37.5 mg/day (Schedule 2/2, Schedule 4/2, and Continuou...
What is the current status of trial NCT00599924?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2005-09. Estimated completion is 2008-11.
What conditions does trial NCT00599924 study?
This clinical trial studies the following conditions: Neoplasms, Colorectal Neoplasms.
What interventions are being tested in trial NCT00599924?
The interventions under investigation include: sunitinib + FOLFOX (DRUG).
Who is sponsoring clinical trial NCT00599924?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00599924 being conducted?
This trial has 3 study locations across Colorado, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00599924's enrollment target sits among peer trials
53 103rd of 158 higher than 55 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia